Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07780630

Creation of a Biological Collection of BRonchiaI and Pulmonary Tissues From Surgical wastE

The biological samples and associated data will facilitate the successful implementation of the research collaboration between Bordeaux University Hospital and the University of Bordeaux on the pathophysiology of bronchopulmonary diseases. In the longer term, this research could lead to the discovery of new therapeutic targets for asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and acute respiratory distress syndrome.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

1 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Bordeaux

Pessac, 33604, France

Location contact

Patrick BERGER, MD, PhD

PRINCIPAL_INVESTIGATOR

Patrick BERGER, PUPH

CONTACT

(+33)05 57 65 65 13

About this study

Bronchial obstructive diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are very common and pose a major public health problem. Asthma affects about 7% and COPD affects 3% of the population in France. In children, the prevalence of asthma is even higher and can reach 15 to 20%. These two diseases are responsible for many hospitalizations and emergency room stays. While asthma mortality has been considerably reduced over the last 30 years, COPD mortality continues to increase to reach the 3rd leading cause of mortality. In COPD, pulmonary hypertension (PH) is a common comorbidity that increases mortality.

In each of these diseases, bronchial remodeling occurs from the beginning of the disease, including in children. Long considered an abnormal process of tissue repair after inflammation, it is now considered to be concomitant with bronchial inflammation. It conditions the prognosis of the disease but its pathophysiological processes remain largely unknown.

In asthma, bronchial remodeling is characterized by epithelial abrasion, pseudo-thickening of the basement membrane, bronchial fibrosis, hypertrophy of the submucosal glands, neoangiogenesis and increased bronchial smooth muscle mass. In the laboratory, the investigators have shown that the mechanisms responsible for this increase in bronchial smooth muscle mass are complex and involve in particular the mitochondria of bronchial smooth muscle in both adults and children.

In COPD, bronchial remodeling is characterized by epithelial metaplasia, hypertrophy of the submucosal glands, peribronchial fibrosis, and increased bronchial smooth muscle mass.

In the laboratory, it has been shown that fibrocytes are involved in peribronchial fibrosis. In addition, at the level of the lung parenchyma, there is a destruction of the distal airway spaces responsible for pulmonary emphysema. In some COPD patients, pulmonary hypertension occurs and is accompanied by remodeling of the pulmonary arteries with thickening of the media, and pulmonary arterial fibrosis.

Apart from adult acute respiratory distress syndrome (ARDS), it is an acute disease with a high risk of secondary pulmonary fibrosis. This is characterized by alveolar fibrosis with a proliferation of fibroblasts.

The COBRA cohort (Bronchial Obstruction and Asthma Cohort), sponsored by INSERM, makes it possible to obtain, with the consent of patients, bronchial tissues, blood, sputum of adult asthma or COPD patients from bronchial biopsies and brushing, Boncho-Alveolar lavage (BAL) obtained during bronchial fiberscopies, blood, sputum.

The results of experiments on asthmatic tissues should be compared with those from non-asthmatic subjects. In adults, these tissues come from surgical waste during lobectomy/pneumonectomy or lung transplantation. In children, these tissues are collected as part of the ARISE, BIRDIES, VIRCHILLD and more recently ICEBERG protocols (all promoted by the Bordeaux University Hospital) which make it possible to perform bronchial brushing and/or bronchial biopsies during bronchial fiberscopy, nasal brushing, surgical waste during a lobectomy and blood. These tissues thus make it possible to cultivate these same smooth muscle cells and bronchial epithelial cells. Adult surgical waste also makes it possible to grow cells from COPD patients at different stages of severity. They also make it possible to extract and culture other cell types involved in the pathophysiology of COPD such as fibrocytes, pneumocytes, endothelial and pulmonary vascular smooth muscle cells and other inflammatory cells such as lymphocytes, neutrophils, macrophages, mast cells, etc. This is because the immune cells in lung tissue are different from those in circulating blood. All of these cell types can be cultured in organoid models of bronchi, alveoli, submucosal glands, or even pulmonary vessels.

Depending on the respiratory function of the operated patients, measured pre-operatively, the bronchial/parenchymal and arterial pulmonary tissues may reflect a "healthy" tissue (non-asthmatic, non-COPD) or mild to severe COPD with or without pulmonary hypertension.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female
  • Adult or children
  • Having required or necessitating, in the context of care or research involving the human person promoted by the Bordeaux University Hospital (ARISE, BIRDIES, ICEBERG, VIRCHILLD) or by Inserm (COBRA), either thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of the Haut Lévêque Hospital, or bronchial fiberscopy with biopsies and/or bronchial brushing and/or BAL at the children's hospital of the Pellegrin Hospital or at the Haut Lévêque Hospital.
  • Having received or, for children whose holders of parental authority have received, an information note with the possibility of opposition in accordance with the MR004 (French law - Commission Nationale de l'Informatique et des Libertés (CNIL))

Exclusion criteria

  • Patient or holder of parental authority for children who have expressed their opposition to participation in the research

Treatment and study plan

Fiberscopic samples

Procedure

Perform brushing and/or bronchial biopsies and/or BAL and/or aspiration during bronchial fiberscopy and surgical waste during a lobectomy.

sputum

Procedure

Sputum has been collected for biological analysis.

nasal brushing

Procedure

Nasal brushing is a minimally invasive medical procedure used to collect cellular samples from the nasal lining by gently rubbing a small cytology brush against the mucosa.

blood sampling

Procedure

Blood sampling is the safe collection of a blood specimen from a vein, finger, or artery to run medical lab tests

Primary outcomes

  1. Describe tobacco consumption

    Time frame: At enrollment

    Number pack in years

  2. Describe tobacco statut

    Time frame: At enrollment

    Described as either non-smokers, former smokers or current smokers

  3. Description of demographic status

    Time frame: At enrollment

    Gender (male or female)

  4. Description of demographic status

    Time frame: At enrollment

    Age as years

  5. Description of demographic status

    Time frame: At enrollment

    Body Mass Index (BMI) (kg/m^2)

  6. Mesure of lung function parameters

    Time frame: At enrollment

    FEV1: forced expiratory volume in 1 sec

  7. Mesure of lung function parameters

    Time frame: At enrollment

    FVC: forced vital capacity

  8. Mesure of lung function parameters

    Time frame: At enrollment

    FEF25-75: forced expiratory flow between 25 and 75% of the FVC

  9. Mesure of lung function parameters

    Time frame: At enrollment

    TLC: total lung capacity

  10. Mesure of lung function parameters

    Time frame: At enrollment

    RV: residual volume

  11. Describe of disease status

    Time frame: At enrollment

    Described as Healthy, COPD or Asthma

  12. Collection type

    Time frame: At enrollment

    Described as bronchial or lung specimens (frozen of embedded in paraffin), bronchial smooth muscle cells, bronchial epithelial cells, alveolar cells, arterial smooth muscle cells, arterial endothelial cells, fibrocytes, mesenchymal cells, lymphocytes, neutrophils, macrophages, organoïds.

Secondary outcomes

  1. Mesure of blood gas parameter

    Time frame: At enrollment

    PaO2: arterial pressure in oxygen,

  2. Mesure of blood gas parameter

    Time frame: At enrollment

    PaCO2: arterial pressure in carbon dioxide

  3. Mesure of blood gas parameter

    Time frame: At enrollment

    pH

Study contacts

Contact information is provided by the study sponsor or research team.

Patrick BERGER, MD, PhD

CONTACT

[email protected]

+33 5 47 30 27 50

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Acronym: BRISE

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 21, 2026
Registry last updated
Aug 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.